Fasenra (benralizumab) is a monoclonal antibody that is approved for children ages 12 and older.
It is an injection that is used to treat Severe Eosinophilic Asthma. It works by directly binding to the alpha subunit of the IL-5 receptor, which recruits natural killer cells to attack eosinophils.
Too many eosinophils can lead to inflammation in your lungs. Reducing the number of blood eosinophils will help decrease airway inflammation, therefore leading to better control of your child’s asthma.
